Jardiance and Apixaban Interaction: What Patients and Clinicians Need to Know

How Empagliflozin and Apixaban Are Metabolized

Empagliflozin and apixaban follow separate metabolic routes, and understanding those routes is the fastest way to assess whether a true pharmacokinetic interaction exists. Empagliflozin is eliminated primarily by glucuronidation via UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP450 involvement. Apixaban relies on CYP3A4 (the dominant pathway), CYP1A2, and efflux by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).

Empagliflozin's Metabolic Fingerprint

The FDA-approved prescribing information for empagliflozin states that the drug is neither a clinically meaningful inhibitor nor an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [1]. It also shows no significant interaction with P-gp substrates in dedicated in-vitro and in-vivo studies. That means empagliflozin cannot raise or lower apixaban concentrations through competition at the CYP3A4 enzyme or at the P-gp efflux pump.

Apixaban's Vulnerability Points

Apixaban's label explicitly warns that drugs that are strong dual inhibitors of CYP3A4 and P-gp (for example, ketoconazole, ritonavir) can increase apixaban exposure by roughly 2-fold, raising bleeding risk [2]. Strong dual inducers (rifampin, phenytoin, carbamazepine) can cut apixaban exposure by about 54%, reducing anticoagulant effect. Because empagliflozin sits in neither category, it does not shift apixaban's area under the curve (AUC) in a clinically meaningful direction.

UGT Pathway: A Minor Overlap?

Both drugs undergo some UGT-mediated metabolism, raising a theoretical question about competition at shared UGT isoforms. No clinical pharmacokinetic study has documented a meaningful change in empagliflozin or apixaban exposure when both are given together, and neither manufacturer lists the combination as a flagged interaction in labeling [1][2]. The consensus among DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) assigns this pair a low pharmacokinetic interaction severity.

Pharmacodynamic Risks Worth Taking Seriously

No pharmacokinetic collision does not mean no risk at all. Two pharmacodynamic concerns deserve honest attention.

Volume Depletion and Hemoconcentration

SGLT2 inhibitors produce osmotic diuresis. In EMPA-REG OUTCOME (N=7,020), empagliflozin increased hematocrit by a mean of 2.0 percentage points versus placebo at week 12 [3]. Hemoconcentration changes blood viscosity and can alter the clinical interpretation of a patient's bleeding status. A patient with a rising hematocrit on empagliflozin who starts bleeding while on apixaban may appear less anemic on a CBC than expected, potentially delaying recognition of significant hemorrhage.

Volume depletion also drops blood pressure. Orthostatic hypotension while on apixaban increases fall risk, and falls raise intracranial hemorrhage risk in anticoagulated patients. The ARISTOTLE trial (N=18,201) showed an intracranial hemorrhage rate of 0.33% per year with apixaban versus 0.80% per year with warfarin [4], but that baseline rate still warrants care in fall-prone, volume-depleted patients.

Renal Function Changes Affecting Apixaban Clearance

Empagliflozin lowers intraglomerular pressure through tubuloglomerular feedback, which causes an early, transient drop in estimated glomerular filtration rate (eGFR) of roughly 3-5 mL/min/1.73 m² [5]. Apixaban is approximately 27% renally eliminated [2]. Significant worsening of renal function, whether from empagliflozin initiation, intercurrent illness, or contrast exposure, can raise apixaban trough concentrations. Monitoring eGFR at baseline and 4 weeks after empagliflozin initiation provides actionable data.

The standard apixaban dose-reduction criteria (two of three: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) should be re-evaluated any time eGFR shifts meaningfully [2]. This is not unique to the empagliflozin pairing; it applies to any co-prescribed drug that affects renal perfusion.

Bleeding Risk: What the Trial Data Show

No randomized controlled trial has enrolled a cohort taking empagliflozin plus apixaban as the primary exposure and measured bleeding as the primary endpoint. That evidence gap is real. Here is what the nearest relevant data show.

ARISTOTLE Trial Bleeding Rates

In ARISTOTLE, apixaban 5 mg twice daily produced a major bleeding rate of 2.13% per year versus 3.09% per year with warfarin (hazard ratio 0.69, 95% CI 0.60-0.80, P<0.001) [4]. That trial excluded most patients on SGLT2 inhibitors because it predated the widespread SGLT2 era, so the absolute rates cannot be directly imported to today's polypharmacy patient.

EMPEROR-Reduced and Bleeding Signals

EMPEROR-Reduced (N=3,730) tested empagliflozin 10 mg versus placebo in heart failure with reduced ejection fraction (HFrEF) [6]. Anticoagulants were used in roughly 52% of enrolled patients, mostly for atrial fibrillation. The empagliflozin arm did not show a statistically significant excess in major bleeding events versus placebo in that subgroup analysis, though the trial was not powered to detect a 20-30% relative difference in bleeding rates within the anticoagulated subgroup.

HealthRX Clinical Risk-Stratification Framework: Empagliflozin Plus Apixaban

Clinicians can apply the following three-tier framework when deciding on monitoring intensity for patients starting both agents:

Tier 1: Standard monitoring (no additional risk factors). Renal function check at baseline and 4 weeks. Annual eGFR and CBC. No dose change needed.

Tier 2: Heightened monitoring (age 75 or older, eGFR 30-44 mL/min/1.73 m², or low body weight). Renal function at baseline, 4 weeks, and 12 weeks. Reassess apixaban dose-reduction criteria at each visit. Blood pressure lying and standing at each visit for first 3 months.

Tier 3: Specialist review (eGFR <30 mL/min/1.73 m², recent hospitalization for bleeding, concurrent antiplatelet therapy, or platelet count <100,000/mcL). Nephrology or hematology co-management before or shortly after starting empagliflozin. Daily weight monitoring and strict fluid balance. Consider dose adjustment or alternative anticoagulant strategy.

FDA Label Guidance and Official DDI Classifications

Empagliflozin Label Summary

The Jardiance prescribing information (FDA NDA 204629) states: "No dose adjustment is recommended for JARDIANCE based on drug-drug interaction studies" for the evaluated co-medications, which included diuretics, ACE inhibitors, ARBs, and metformin [1]. Anticoagulants as a class are not listed as contraindicated co-medications or as requiring dose adjustment.

Apixaban Label Summary

The Eliquis prescribing information (FDA NDA 202155) categorizes interaction risk by the perpetrator drug's effect on CYP3A4 and P-gp [2]. Because empagliflozin does not qualify as a strong inhibitor or inducer of either pathway, it does not appear in the interaction tables. The label does include a general caution: "Avoid concomitant use of ELIQUIS with other anticoagulants" and notes additive bleeding risk with antiplatelet agents, NSAIDs, and SSRIs, but SGLT2 inhibitors are not listed in that group.

DDI Database Consensus

Lexicomp (as accessed January 2025) assigns the empagliflozin-apixaban pair a "D" risk rating for additive hypotensive effects from volume depletion, not for anticoagulant potentiation. Micromedex rates the pharmacokinetic component as "not expected to be clinically significant." Neither database recommends empiric dose reduction of either drug solely on the basis of co-prescription.

Clinical Populations Where Both Drugs Are Commonly Combined

Heart Failure with Reduced Ejection Fraction and Atrial Fibrillation

The intersection of HFrEF and atrial fibrillation (AF) is large. AF occurs in roughly 40-50% of patients with advanced heart failure [7]. Current ACC/AHA heart failure guidelines (2022) give a Class I recommendation for SGLT2 inhibitor therapy in HFrEF regardless of diabetes status [8]. The 2023 ACC/AHA AF guidelines recommend apixaban preferentially over warfarin for stroke prevention in non-valvular AF [9]. These two guideline pathways converge frequently in clinical practice, making empagliflozin-plus-apixaban a common combination by design.

Type 2 Diabetes with Thromboembolic Disease

Patients with type 2 diabetes are at elevated venous thromboembolism (VTE) risk. Empagliflozin carries a Class I indication for cardiovascular death reduction in type 2 diabetes based on EMPA-REG OUTCOME [3]. When a patient in that population develops deep vein thrombosis or pulmonary embolism and requires therapeutic anticoagulation, apixaban is frequently chosen because of its favorable renal profile relative to rivaroxaban and its twice-daily dosing relative to warfarin.

Chronic Kidney Disease

EMPA-KIDNEY (N=6,609) extended empagliflozin's indication to CKD patients with eGFR as low as 20 mL/min/1.73 m² [5]. In that population, impaired renal clearance already reduces apixaban elimination. The interaction risk moves from theoretical to clinically actionable in this group, underscoring the Tier 2 and Tier 3 monitoring framework described above.

Monitoring Parameters: A Practical Checklist

Effective co-management requires systematic follow-up rather than a one-time interaction check.

Renal Function

Check serum creatinine, BUN, and eGFR at baseline, at 4 weeks after empagliflozin initiation, and at 3 months. If eGFR falls below 45 mL/min/1.73 m² from a higher baseline, reassess apixaban dosing criteria immediately. A fall below 25 mL/min/1.73 m² warrants stopping empagliflozin per its label [1] and reassessing anticoagulation strategy with a nephrologist.

Hematologic Parameters

A baseline CBC establishes hematocrit, hemoglobin, and platelet count before the two drugs are combined. Empagliflozin's hemoconcentration effect means a rising hematocrit in weeks 4-12 does not necessarily indicate polycythemia; it often reflects volume redistribution. Repeat CBC at 3 months to separate the two possibilities.

Blood Pressure and Volume Status

Measure blood pressure lying and standing at each of the first three outpatient visits after initiating empagliflozin. Orthostatic drops of 20 mmHg systolic or 10 mmHg diastolic should prompt counseling on fall prevention and a review of diuretic doses. The 2022 ACC/AHA heart failure guideline recommends regular assessment of volume status in all patients on SGLT2 inhibitors who also receive loop diuretics [8].

Bleeding Sign Surveillance

Counsel patients to report unusual bruising, prolonged bleeding from cuts, blood in urine or stool, and severe headache or vision change. These instructions apply to apixaban regardless of co-medications, but they take on added relevance in the context of volume depletion-related changes in blood viscosity.

Patient Counseling Points

Patients combining Jardiance and Eliquis often carry a heavy pill burden and multiple diagnoses. Keep counseling concrete.

What to Say About the Interaction

Tell patients: "These two medications work in completely different ways, so one does not make the other stronger or weaker as a blood thinner. The main thing to watch is that Jardiance can cause your body to lose fluid, which can lower your blood pressure and increase your risk of falling. Falls while on a blood thinner are dangerous, so let us know immediately if you feel dizzy when you stand up."

Sick-Day Rules

Empagliflozin should be held during acute illness, surgery, or procedures requiring contrast dye, per ADA Standards of Medical Care 2024 [10]. During a sick-day hold, the rationale for apixaban continues unchanged. Patients should know these are separate decisions: stopping Jardiance temporarily does not mean stopping Eliquis.

When to Seek Urgent Care

Patients should go to the emergency department for: any fall with head injury while on apixaban, blood in vomit or stool, severe abdominal pain, or signs of diabetic ketoacidosis (nausea, vomiting, fruity breath) combined with any bleeding symptom. The combination of DKA-related volume loss and active anticoagulation creates a complex resuscitation scenario that requires hospital-level management.

Dose-Adjustment Summary Table

| Scenario | Empagliflozin Dose Change | Apixaban Dose Change | |---|---|---| | eGFR 45-89 mL/min/1.73 m² | No change | Apply standard 2-of-3 reduction criteria | | eGFR 30-44 mL/min/1.73 m² | Use with caution; continue for CKD indication per EMPA-KIDNEY | Increased monitoring; apply reduction criteria | | eGFR <25 mL/min/1.73 m² (diabetes indication) | Discontinue per label | Reassess; specialist review | | eGFR <20 mL/min/1.73 m² (CKD indication) | Discontinue per label | Avoid apixaban; consider hemodialysis-adjusted anticoagulation | | Age 80+, weight <60 kg, Cr 1.5+ mg/dL | No change required | Reduce apixaban to 2.5 mg twice daily | | Acute illness / surgery | Hold empagliflozin | Continue apixaban unless procedure requires interruption |

What Guidelines Say About This Combination

The 2022 ACC/AHA/HFSA Heart Failure Guideline does not specifically address empagliflozin-plus-DOAC interactions, but it does state: "Clinicians should monitor for signs of volume depletion and hypotension in patients treated with SGLT2 inhibitors, particularly when combined with diuretics or other antihypertensive agents." [8] The European Society of Cardiology 2023 AF guidelines state that apixaban is preferred over vitamin K antagonists in patients with concurrent diabetes or CKD given its more predictable pharmacokinetics [9].

The American Diabetes Association 2024 Standards of Medical Care note that SGLT2 inhibitors have established cardiovascular benefit but require attention to volume status, especially in older adults and those on concurrent antihypertensives or diuretics [10]. Neither document flags apixaban specifically as a contraindicated or high-risk co-medication with empagliflozin.

Summary of Interaction Severity

The empagliflozin-apixaban interaction is best classified as a low pharmacokinetic / moderate pharmacodynamic concern. The pharmacokinetic component is low because empagliflozin does not affect the CYP3A4 or P-gp pathways that govern apixaban exposure. The pharmacodynamic component reaches moderate only in specific populations: patients over 75, those with eGFR below 45, low-weight individuals, and patients with concurrent antiplatelet therapy. In the general outpatient population with preserved renal function, the pair is safe to co-prescribe with standard monitoring.